Key regions: United Kingdom, Canada, Japan, Europe, China
The demand for dermatological drugs in Tajikistan has been steadily increasing in recent years.
Customer preferences: Tajikistan has a predominantly young population, with almost 70% of the population under the age of 30. This demographic is more likely to be affected by skin conditions, such as acne and eczema, leading to a higher demand for dermatological drugs. Additionally, the country has a high prevalence of infectious skin diseases, such as scabies and leprosy, which also contribute to the demand for dermatological drugs.
Trends in the market: The dermatological drugs market in Tajikistan is largely driven by the increasing availability of affordable generic drugs. The government has implemented policies to encourage the use of generic drugs, which has led to a decrease in the prices of dermatological drugs. This has made them more accessible to the general population. Additionally, there has been an increase in the number of dermatology clinics in the country, which has led to an increase in the number of prescriptions for dermatological drugs.
Local special circumstances: The healthcare infrastructure in Tajikistan is still developing, and there are limited resources available for the treatment of skin conditions. This has led to a reliance on dermatological drugs as the primary treatment option. Additionally, there is a lack of public awareness about the importance of skin health, leading to a delay in seeking treatment for skin conditions.
Underlying macroeconomic factors: Tajikistan is a low-income country with a large rural population. The cost of healthcare is a significant burden for many households, leading to a preference for affordable generic drugs. Additionally, the country has a high burden of infectious diseases, which has led to an increased demand for dermatological drugs. The government has implemented policies to improve access to healthcare, which has contributed to the growth of the dermatological drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
